Skip to Content

Poniard Pharmaceuticals Inc PARD

Morningstar Rating
$0.00 0.00 (0.99%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

PARD is trading at a 58% discount.
Price
$0.00
Fair Value
$5.99
Uncertainty
Extreme
1-Star Price
$1.28
5-Star Price
Economic Moat
Kmtc
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if PARD is a good fit for your portfolio.

Trading Information

Previous Close Price
$0.00
Day Range
$0.000.00
52-Week Range
$0.000.00
Bid/Ask
$0.00 / $0.31
Market Cap
$149.92
Volume/Avg
159 / 13,061

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Poniard Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of cancer therapeutics. Its product candidate is picoplatin, a new generation platinum-based cancer therapy.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
8

Valuation

Metric
PARD
Price/Earnings (Normalized)
Price/Book Value
Price/Sales
Price/Cash Flow
Price/Earnings
No chart available

Financial Strength

Metric
PARD
Quick Ratio
0.67
Current Ratio
0.76
Interest Coverage
Quick Ratio
No chart available

Profitability

Metric
PARD
Return on Assets (Normalized)
−92.17%
Return on Equity (Normalized)
−170.51%
Return on Invested Capital (Normalized)
−108.56%
Return on Assets
No chart available
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRXwsbnzxydtGdjv$558.5 Bil
VRTX
Vertex Pharmaceuticals IncMtfvrppDwkjkml$103.4 Bil
REGN
Regeneron Pharmaceuticals IncDfszzzyvTqdwzyq$102.8 Bil
MRNA
Moderna IncVgrtryxRvpq$41.0 Bil
BNTX
BioNTech SE ADRTxbpydqjDtkr$21.7 Bil
ALNY
Alnylam Pharmaceuticals IncZvqrddrLszvbk$19.7 Bil
BMRN
Biomarin Pharmaceutical IncFcwglssxZxhbvdt$17.4 Bil
RPRX
Royalty Pharma PLC Class AHdpxzgpfblTfrcjsz$13.0 Bil
INCY
Incyte CorpWwdzmtkmXrcddrp$12.4 Bil
UTHR
United Therapeutics CorpSkxnglqrVcz$11.2 Bil

Sponsor Center